Real-world toxicity and effectiveness of ixazomib, lenalidomide, and dexamethasone in Korean patients with relapsed and/or refractory multiple myeloma.
Ji Hyun LeeSung-Hyun KimHye Ryeon KimChang-Ki MinJe-Jung LeeHo-Jin ShinJae-Cheol JoJi Yun LeeJoon Ho MoonKihyun KimPublished in: International journal of hematology (2022)
Ixazomib and Rd combination therapy had a comparable toxicity profile and effectiveness in real-world RRMM patients.